Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide

Experimental Eye Research

Volumn 79, Issue 4, 2004, Pages 525-535

  Marano, Robert J ^a   Wimmer, Norbert ^b   Kearns, Philip S ^b   Thomas, Bradley G ^b   Toth, Istvan ^b   Brankov, Meliha ^a   Rakoczy, P Elizabeth ^a,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

cationic lipids; choroid; dendrimer; laser photocoagulation; lipidic polyamide; lipoamino acids; oligonucleotide; transfection; VEGF

Indexed keywords

DENDRIMER; LIPID; LYSINE; MESSENGER RNA; OLIGONUCLEOTIDE; VASCULOTROPIN;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; DRUG DELIVERY SYSTEM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ANGIOGRAPHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LASER; LIPOGENESIS; LIPOPHILICITY; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBRETINAL NEOVASCULARIZATION;

ANIMALS; CELLS, CULTURED; CHOROIDAL NEOVASCULARIZATION; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; OLIGONUCLEOTIDES; RATS; RATS, INBRED STRAINS; RNA, MESSENGER; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 4544332801     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2004.06.023     Document Type: Article

References (32)

1. T. Abe, and S. Suzuki Specific inhibition of influenza virus RNA polymerase and nucleoprotein gene expression by liposomally encapsulated antisense phosphorothioate oligonucleotides in MDCK cells Antivir. Chem. Chemother. 9 1998 253 262
2. A.P. Adamis, and J.W. Miller Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy Am. J. Ophthalmol. 118 1994 445 450
3. L.P. Aiello, and E.A. Pierce Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins Proc. Natl. Acad. Sci. USA 92 1995 10457 10461
4. S. Akhtar, and M.D. Hughes The delivery of antisense therapeutics Adv. Drug Deliv. Rev. 44 2000 3 21
5. S.K. Alahari, and N.M. Dean Inhibition of expression of the multidrug resistance-associated P-glycoprotein of by phosphorothioate and 5′ cholesterol-conjugated phosphorothioate antisense oligonucleotides Mol. Pharmacol. 50 1996 808 819
6. J.W. Bainbridge, and A. Mistry Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1 Gene Ther. 9 2002 320 326
7. V.A. Bloomfield DNA condensation Curr. Opin. Struct. Biol. 6 1996 334 341
8. J.S. Cohen Oligonucleotides as therapeutic agents Pharmacol. Ther. 52 1991 211 225
9. S.T. Crooke Progress toward oligonucleotide therapeutics: pharmacodynamic properties Fed. Am. Soc. Exp. Biol. J. 7 1993 533 539
10. N. Duzgunes, and P.L. Felgner Intracellular delivery of nucleic acids and transcription factors by cationic liposomes Methods Enzymol. 221 1993 303 306
11. J.A. Forsythe, and B.H. Jiang Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 Mol. Cell Biol. 16 1996 4604 4613
12. E. Freire, O.L. Mayorga, and M. Straume Isothermal titration Anal. Chem. 1990 950A 959A
13. M.J. Gait Peptide-mediated cellular delivery of antisense oligonucleotides and their analogues Cell. Mol. Life Sci. 60 2003 844 853
14. K.L. Garrett, W.Y. Shen, and P.E. Rakoczy In vivo use of oligonucleotides to inhibit choroidal neovascularisation in the eye J. Gene Med. 3 2001 373 383
15. W.A. Gibbons, and R.A. Hughes Synthesis, resolution and structural elucidation of lipidic amino acids and their homo- and hetero-oligomers Liebigs Ann. Chem. 1990 1175 1183
16. S. Gryaznov, and T. Skorski Oligonucleotide N3′→P5′ phosphoramidates as antisense agents Nucl. Acids Res. 24 1996 1508 1514
17. J.F. Kukowska-Latallo, and A.U. Bielinska Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers Proc. Natl. Acad. Sci. USA 93 1996 4897 4902
18. A. Kvanta, P.V. Algvere, L. Berglin, and S. Seregard Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor Invest. Ophthalmol. Vis. Sci. 37 1996 1929 1934
19. H.M. Leibowitz, and D.E. Krueger The Framingham eye study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975 Surv. Ophthalmol. 24 1980 335 610
20. N.S. Levy, M.A. Goldberg, and A.P. Levy Sequencing of the human vascular endothelial growth factor (VEGF) 3′ untranslated region (UTR): conservation of five hypoxia-inducible RNA-protein binding sites Biochim. Biophys. Acta. 1352 1997 167 173
21. L.X. Liu, and H. Lu Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor 1 Biochem. Biophys. Res. Commun. 291 2002 908 914
22. B.A. Lobo, and S.A. Rogers Characterisation of cationic vector-based gene delivery using isothermal titration and differential scanning calorimetry Methods Mol. Med. 65 2001 319 348
23. R.B. Merrifield Solid-phase pepitide synthesis. 1. The synthesis of a tetrapeptide J. Am. Chem. Soc. 85 1963 2149 2154
24. D.L. Miller, and J.A. Dibbens The vascular endothelial growth factor mRNA contains an internal ribosome entry site Fed. Eur. Biochem. Soc. Lett. 434 1998 417 420
25. D.S. Shah, T. Sakthivel, I. Toth, A.T. Florence, and A.F. Wilderspin DNA transfection and transfected cell viability using amphipathic asymmetric dendrimers Int. J. Pharm. 208 2000 41 48
26. W.Y. Shen, and P.E. Rakoczy Uptake dynamics and retinal tolerance of phosphorothioate oligonucleotide and its direct delivery into the site of choroidal neovascularization through subretinal administration in the rat Antisense Nucl. Acid Drug Dev. 11 2001 257 264
27. A. Sommer, and J.M. Tielsch Racial differences in the cause-specific prevalence of blindness in east Baltimore N. Engl. J. Med. 325 1991 1412 1417
28. C.A. Stein, and Y.C. Cheng Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science 261 1993 1004 1012
29. J.R.H. Tame, R. O'Brian, J.I. Ladbury, and B.Z. Chowdhry Isothermal titration calorimetry of biomolecules J.I. Ladbury B.Z. Chowdhry Biocalorimetry, Applications of Calorimetry in the Biological Sciences 1998 Wiley Chichester 27 38
30. E. Urban, and C.R. Noe Structural modifications of antisense oligonucleotides Il Farmaco 58 2003 243 258
31. E. Wagner Application of membrane-active peptides for nonviral gene delivery Adv. Drug Deliv. Rev. 38 1999 279 289
32. N. Wimmer, R.J. Marano, P.S. Kearns, E.P. Rakoczy, and I. Toth Syntheses of polycationic dendrimers on lipophilic peptide core for complexation and transport of oligonucleotides Bioorg. Med. Chem. Lett. 12 2002 2635 2637